John Gustofson
Founder & President @ Chugai Venture Fund
Boston, United States
John Gustofson is a Series A investor at Chugai Venture Fund in Boston focused on Biotechnology and Medical. John Gustofson is the Founder and President of Chugai Venture Fund. He previously worked at AbbVie as a Managing Director. John Gustofson attended Questrom School of Business, Boston University.
- Total investments:
- 10
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries John Gustofson invests in
Stages John Gustofson invests in
Countries John Gustofson invests in
Investment Focus
Industry
- Biotechnology 4 (40%)
- Medical 2 (20%)
- Health Care 2 (20%)
- Therapeutics 2 (20%)
- Pharmaceutical 2 (20%)
Stage
- Series A 4 (40%)
- Seed 1 (10%)
- Funding Round 1 (10%)
- Debt Financing 1 (10%)
- Venture - Series Unknown 1 (10%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ten63 Therapeutics
|
Ten63 Therapeutics is a venture-backed startup developing durable therapeutics against some of the most lethal diseases. It combines low-residual, ML-based computational chemistry and mathematically guaranteed, superlinear search algorithms to find optimized drug candidates. The company's platform, COPPER, leverages its proprietary AI andstate-of-the-art physical models to explore an unprecedentedly large chemical space, allowing them to discover new therapeutics to targets previously believed undruggable. | Venture - Series Unknown / Feb 19, 2026 | |
Leal Therapeutics
|
Leal Therapeutics develops novel therapeutics for patients. | $30M / Series A / Aug 27, 2025 | |
Stylus Medicine
|
Stylus Medicine is on a quest to create disease-treating agents for the next generation based on the groundbreaking work of its founders. The company is based in Cambridge, Massachusetts. | $85M / Series A / May 12, 2025 | |
|
Leal Therapeutics
|
Leal Therapeutics develops novel therapeutics for patients. | Debt Financing / Oct 30, 2024 | |
|
Leal Therapeutics
|
Leal Therapeutics develops novel therapeutics for patients. | $6M / Venture - Series Unknown / Oct 30, 2024 | |
Caraway Therapeutics
|
Rheostat’s mission is to invent novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy. They believe that the degradation of toxic cellular components, whether they are damaged organelles or aggregated proteins, is a fundamental node of biology. Mutations that impair these clearance pathways cause multipleneurodegenerative diseases, many of which are associated with cognitive impairment. They aim to leverage our understanding of these critical pathways to discover and develop novel small molecules that will restore cellular balance and treat neurodegenerative and rare diseases. | $23M / Series A / Nov 26, 2018 | |
|
Caraway Therapeutics
|
Rheostat’s mission is to invent novel treatments for neurodegenerative disease through modulation of mitophagy and autophagy. They believe that the degradation of toxic cellular components, whether they are damaged organelles or aggregated proteins, is a fundamental node of biology. Mutations that impair these clearance pathways cause multipleneurodegenerative diseases, many of which are associated with cognitive impairment. They aim to leverage our understanding of these critical pathways to discover and develop novel small molecules that will restore cellular balance and treat neurodegenerative and rare diseases. | $23M / Series A / Nov 26, 2018 | |
Ribometrix
|
Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston. | $30M / Series A / Nov 13, 2018 | |
|
Ribometrix
|
Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston. | $7.5M / Seed / Oct 31, 2017 | |
|
Ribometrix
|
Ribometrix is a platform therapeutics company that discovers small molecule drugs that target functional 3D RNA structures to treat human diseases. Our scientific offices are located in the newly renovated Biolabs Space in Durham, with offices in Chapel Hill and Boston. | $7.5M / Seed / Oct 31, 2017 |
Co-Investors
About Chugai Venture Fund
Chugai Venture Fund is a pioneering investment firm that promotes innovation and creates revolutionary improvements in the life sciences industry.
Chugai Venture Fund Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
John Gustofson
Founder & President
|
|||
Mike Dial
Managing Director
|
|||
3 more contacts available
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does John Gustofson invest in?
John Gustofson invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Seed stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did John Gustofson last invest?
The most recent investment recorded for John Gustofson closed in Feb 2026. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
